Quest Diagnostics Inc. (DGX)

$138.19

-0.72

(-0.52%)

Market is closed - opens 7 PM, 30 May 2024

Insights on Quest Diagnostics Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 2.28B → 2.36B (in $), with an average increase of 3.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 192.0M → 194.0M (in $), with an average increase of 1.0% per quarter

  • Vs A

    In the last 1 year, Agilent Technologies Inc. has given 23.6% return, outperforming this stock by 20.4%

  • Vs TMO

    In the last 3 years, Thermo Fisher Scientific, Inc. has given 5.3% return, outperforming this stock by 0.3%

Performance

  • $137.34
    $139.00
    $138.19
    downward going graph

    0.62%

    Downside

    Day's Volatility :1.19%

    Upside

    0.58%

    downward going graph
  • $117.60
    $145.62
    $138.19
    downward going graph

    14.9%

    Downside

    52 Weeks Volatility :19.24%

    Upside

    5.1%

    downward going graph

Returns

PeriodQuest Diagnostics Inc.Sector (Health Care)S&P500
3 Months
10.65%
-2.3%
3.3%
6 Months
0.7%
7.8%
15.3%
1 Year
3.22%
11.7%
25.2%
3 Years
8.58%
14.5%
25.3%

Highlights

Market Capitalization
15.4B
Book Value
$57.95
Dividend Share
2.88
Dividend Yield
2.12%
Earnings Per Share (EPS)
7.31
PE Ratio
19.0
PEG Ratio
1.52
Wall Street Target Price
147.07
Profit Margin
9.11%
Operating Margin TTM
13.4%
Return On Assets TTM
6.2%
Return On Equity TTM
14.15%
Revenue TTM
9.3B
Revenue Per Share TTM
83.11
Quarterly Revenue Growth YOY
1.5%
Gross Profit TTM
3.5B
EBITDA
1.8B
Diluted Eps TTM
7.31
Quarterly Earnings Growth YOY
-0.03
EPS Estimate Current Year
8.83
EPS Estimate Next Year
9.48
EPS Estimate Current Quarter
1.85
EPS Estimate Next Quarter
2.35

Analyst Recommendation

Hold
    40%Buy
    59%Hold
    0
    0%Sell
Based on 22 Wall street analysts offering stock ratings for Quest Diagnostics Inc.(by analysts ranked 0 to 5 stars)
Based on 22 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
8
Hold
13
13
13
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 6.43%

Current $138.19
Target $147.07

Company Financials

FY18Y/Y Change
Revenue
7.5B
↓ 2.31%
Net Income
736.0M
↓ 4.66%
Net Profit Margin
9.77%
↓ 0.24%
FY19Y/Y Change
Revenue
7.7B
↑ 2.59%
Net Income
858.0M
↑ 16.58%
Net Profit Margin
11.11%
↑ 1.34%
FY20Y/Y Change
Revenue
9.4B
↑ 22.15%
Net Income
1.4B
↑ 66.78%
Net Profit Margin
15.16%
↑ 4.05%
FY21Y/Y Change
Revenue
10.8B
↑ 14.32%
Net Income
2.0B
↑ 39.41%
Net Profit Margin
18.49%
↑ 3.33%
FY22Y/Y Change
Revenue
9.9B
↓ 8.39%
Net Income
946.0M
↓ 52.58%
Net Profit Margin
9.57%
↓ 8.92%
FY23Y/Y Change
Revenue
9.3B
↓ 6.38%
Net Income
854.0M
↓ 9.73%
Net Profit Margin
9.23%
↓ 0.34%
Q4 FY22Q/Q Change
Revenue
2.3B
↓ 6.15%
Net Income
101.0M
↓ 60.24%
Net Profit Margin
4.33%
↓ 5.89%
Q1 FY23Q/Q Change
Revenue
2.3B
↓ 0.09%
Net Income
202.0M
↑ 100.0%
Net Profit Margin
8.67%
↑ 4.34%
Q2 FY23Q/Q Change
Revenue
2.3B
↑ 0.3%
Net Income
235.0M
↑ 16.34%
Net Profit Margin
10.05%
↑ 1.38%
Q3 FY23Q/Q Change
Revenue
2.3B
↓ 1.84%
Net Income
225.0M
↓ 4.26%
Net Profit Margin
9.8%
↓ 0.25%
Q4 FY23Q/Q Change
Revenue
2.3B
↓ 0.31%
Net Income
192.0M
↓ 14.67%
Net Profit Margin
8.39%
↓ 1.41%
Q1 FY24Q/Q Change
Revenue
2.4B
↑ 3.41%
Net Income
194.0M
↑ 1.04%
Net Profit Margin
8.2%
↓ 0.19%
FY18Y/Y Change
Total Assets
11.0B
↑ 4.76%
Total Liabilities
5.7B
↑ 3.49%
FY19Y/Y Change
Total Assets
12.8B
↑ 16.72%
Total Liabilities
7.1B
↑ 25.11%
FY20Y/Y Change
Total Assets
14.0B
↑ 9.21%
Total Liabilities
7.1B
↑ 0.78%
FY21Y/Y Change
Total Assets
13.6B
↓ 2.96%
Total Liabilities
7.0B
↓ 1.21%
FY22Y/Y Change
Total Assets
12.8B
↓ 5.69%
Total Liabilities
6.8B
↓ 3.11%
FY23Y/Y Change
Total Assets
14.0B
↑ 9.23%
Total Liabilities
7.6B
↑ 11.33%
Q4 FY22Q/Q Change
Total Assets
12.8B
↓ 2.92%
Total Liabilities
6.8B
↓ 0.64%
Q1 FY23Q/Q Change
Total Assets
12.8B
↓ 0.33%
Total Liabilities
6.6B
↓ 2.94%
Q2 FY23Q/Q Change
Total Assets
13.4B
↑ 4.93%
Total Liabilities
7.1B
↑ 6.52%
Q3 FY23Q/Q Change
Total Assets
13.5B
↑ 0.42%
Total Liabilities
6.9B
↓ 1.67%
Q4 FY23Q/Q Change
Total Assets
14.0B
↑ 4.01%
Total Liabilities
7.6B
↑ 9.52%
Q1 FY24Q/Q Change
Total Assets
14.0B
↓ 0.48%
Total Liabilities
7.4B
↓ 2.58%
FY18Y/Y Change
Operating Cash Flow
1.2B
↑ 2.13%
Investing Cash Flow
-801.0M
↓ 0.5%
Financing Cash Flow
-401.0M
↓ 32.26%
FY19Y/Y Change
Operating Cash Flow
1.2B
↑ 3.58%
Investing Cash Flow
-411.0M
↓ 48.69%
Financing Cash Flow
225.0M
↓ 156.11%
FY20Y/Y Change
Operating Cash Flow
2.0B
↑ 61.3%
Investing Cash Flow
-772.0M
↑ 87.83%
Financing Cash Flow
-1.3B
↓ 663.11%
FY21Y/Y Change
Operating Cash Flow
2.2B
↑ 11.37%
Investing Cash Flow
21.0M
↓ 102.72%
Financing Cash Flow
-2.5B
↑ 100.47%
FY22Y/Y Change
Operating Cash Flow
1.7B
↓ 23.06%
Investing Cash Flow
-543.0M
↓ 2685.71%
Financing Cash Flow
-1.7B
↓ 31.81%
Q4 FY22Q/Q Change
Operating Cash Flow
334.0M
↓ 33.47%
Investing Cash Flow
-543.0M
↑ 360.17%
Financing Cash Flow
-545.0M
↑ 14.98%
Q1 FY23Q/Q Change
Operating Cash Flow
94.0M
↓ 71.86%
Investing Cash Flow
-158.0M
↓ 70.9%
Financing Cash Flow
-76.0M
↓ 86.06%
Q2 FY23Q/Q Change
Operating Cash Flow
444.0M
↑ 372.34%
Investing Cash Flow
-840.0M
↑ 431.65%
Financing Cash Flow
189.0M
↓ 348.68%
Q3 FY23Q/Q Change
Operating Cash Flow
207.0M
↓ 53.38%
Investing Cash Flow
-947.0M
↑ 12.74%
Financing Cash Flow
-83.0M
↓ 143.92%

Technicals Summary

Sell

Neutral

Buy

Quest Diagnostics Inc. is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Quest Diagnostics Inc.
Quest Diagnostics Inc.
0.01%
0.7%
3.22%
8.58%
43.95%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
1.13%
6.98%
6.89%
-9.49%
99.58%
Agilent Technologies Inc.
Agilent Technologies Inc.
6.16%
13.83%
23.57%
6.03%
117.49%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-0.25%
14.43%
10.32%
26.91%
111.69%
Danaher Corp.
Danaher Corp.
3.78%
14.61%
12.66%
4.37%
93.24%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-2.92%
5.09%
11.58%
-5.16%
65.28%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Quest Diagnostics Inc.
Quest Diagnostics Inc.
19.0
19.0
1.52
8.83
0.14
0.06
0.02
57.95
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
49.99
49.99
4.75
11.05
0.72
0.23
NA
18.93
Agilent Technologies Inc.
Agilent Technologies Inc.
34.8
34.8
2.7
5.5
0.21
0.08
0.01
21.12
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
37.45
37.45
2.81
21.71
0.14
0.05
0.0
119.24
Danaher Corp.
Danaher Corp.
48.27
48.27
3.13
7.61
0.08
0.04
0.0
72.16
Iqvia Holdings Inc.
Iqvia Holdings Inc.
30.74
30.74
1.33
11.08
0.22
0.05
NA
34.82
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Quest Diagnostics Inc.
Quest Diagnostics Inc.
Hold
$15.4B
43.95%
19.0
9.11%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$41.7B
99.58%
49.99
23.26%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$42.6B
117.49%
34.8
18.35%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$218.6B
111.69%
37.45
14.2%
Danaher Corp.
Danaher Corp.
Buy
$191.6B
93.24%
48.27
18.55%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$41.0B
65.28%
30.74
9.01%

Institutional Holdings

  • Vanguard Group Inc

    12.53%
  • BlackRock Inc

    9.52%
  • State Street Corporation

    4.80%
  • Victory Capital Management Inc.

    3.53%
  • American Century Companies Inc

    3.49%
  • Wellington Management Company LLP

    2.37%

Corporate Announcements

  • Quest Diagnostics Inc. Dividends March,2024

    In the quarter ending March,2024. Quest Diagnostics Inc. has declared dividend of $0.71

    Read More

Company Information

quest diagnostics (nyse: dgx) empowers people to take action to improve health outcomes. derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. quest annually serves one in three adult americans and half the physicians and hospitals in the united states, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. the company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (ap) services, & interpretive consultation through its medical & scientific staff of about 900 m.d.s & ph.d.s. the company reported 2014 revenues of $7.4 billion. quest diagnostics offers the most extensive clinical testing network in the u.s., with laborator

Organization
Quest Diagnostics Inc.
Employees
50000
CEO
Mr. James E. Davis
Industry
Health Services

FAQs